Drug Profile
Research programme: haemangioblast derived mesenchymal stem cell therapies - Stem Cell and Regenerative Medicine International
Alternative Names: Hemangioblast cell programme - Astellas; Hemangioblast derived MSCs - AstellasLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Advanced Cell Technology
- Developer Advanced Cell Technology; Astellas Pharma; Stem Cell & Regenerative Medicine International
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Crohn's disease; Lupus nephritis; Wounds
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Crohn's-disease in USA (Parenteral)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Lupus-nephritis in USA (Parenteral)
- 21 Dec 2018 Astellas Pharma plans to submit IND application for Lupus nephritis and Crohn's disease in 2020